• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2024.19002

Comparative analysis of vascular lesion biomarkers in cardiovascular, metabolic and immuno-inflammatory pathologies

[Internal diseases]
Aida Rufatovna Babaeva; Mikhail Osadchuk; Karina Sergeevna Solodenkova; Andrey Anatolyevich Tarasov;

This analysis was carried out in term to assess the pathogenic role of endothelial dysfunction, systemic inflammation and autoimmunity in cardiovascular, metabolic and immune inflammatory disorders specific biomarkers: endothelin-1, von Willebrand factor, endothelial NO-synthase, TNF-α, IL-1, IL-6 and antibodies to connective tissue components were investigated in 160 patients with CIHD, 132 patients with type 2 diabetes, 94 pts with obesity and/or metabolic syndrome, 124 rheumatoid arthritis pts, 94 AH pts and 40 healthy persons by ELISA. It has been established that the levels of the studied biomarkers in the blood serum of patients with CIHD, type 2 diabetes and O/MS does not reach the values characteristic of RA, but significantly exceed the corresponding values in patients with AH and healthy individuals. The results are obtained the confirm role of immune inflammation in the development of vascular lesions in atherosclerosis and metabolic disorders and are useful in the clinical practice.

Download

References:
1. Glushchenko V. A., Irklienko E. K. Cardiovascular morbidity is one of the most important public health problems. Medicina i organizacija zdravoohranenija. – Medicine and health care organization. 2019;4(1):56-60. (In Russ.).
2. Russian statistical yearbook 2021. Moscow: Stat. sb./Rosstat, 2021. (In Russ.).
3. Belialov F. I. Clinical guidelines for cardiology and comorbid diseases. Moscow: GEOTAR-Media, 2020. (In Russ.).
4. Dedov I. I., Shestakova M. V., Mayorov A. Yu. Standards of specialized diabetes care. Saharnyj diabet. – Diabetes mellitus. 2021;24(suppl.1). (In Russ.). https://doi.org/10.14341/DM12802
5. Dedov I. I., Shestakova M. V., Melnichenko G. A., Mazurina N. V., Andreeva E. N. [et al.]. Interdisciplinary clinical guidelines «Treatment of obesity and comorbid diseases». Ozhirenie i metabolism. – Obesity and metabolism. 2021;18(1):5-99. (In Russ.). https://doi.org/10.14341/omet12714
6. 2020 Clinical practice guidelines for Stable coronary artery disease. Rossijskij kardiologicheskij zhurnal. – Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.). https://doi.org/10.15829/1560-4071-2020-4076
7. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
8. Nasonova Е. L. Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-M (In Russ.).
9. Bryant R. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. https://doi.org/10.1136/bmj.k1036
10. Peluso R., Caso F., Tasso M., Ambrosino P., Di Minno M. N. D. [et al.]. Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. Rev. Recent. Clin. Trials. 2018;13(3):199-209. https://doi.org/10.2174/1574887113666180314105511
11. Baena-Díez J. M., Garcia-Gil M., Comas-Cufí M., Ramos R., Prieto-Alhambra D. [et al.]. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart. 2018;104(2):119-126. https://doi.org/10.1136/heartjnl-2017-311279
12. Fomicheva O. A., Popkova T. V., Krugly L. B., Gerasimova E. V., Novikova D. S. [et al.]. Factors of progression and development of atherosclerosis in rheumatoid arthritis. Kardiologija. – Cardiology. 2021;61(1):12-21. (In Russ.). https://doi.org/10.18087/cardio.2021.1.n1331
13. American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes – 2022. Diabetes Care. 2022;45(suppl.1):S46-S59. https://doi.org/10.2337/dc22-S004
14. Chazova I. E., Shestakova M. V., Zhernakova Y. V., Markova T. N., Mazurina N. V. [et al.]. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Sistemnye gipertenzii. – Sustemic Hypertension 2020;17(1):7-45. (In Russ.). https://doi.org/10.26442/2075082X.2020.1.200051
15. Agarkov N. M., Markelova E. A., Markelov M. Yu., Konyaev D. A., Lutai Yu. A. Cytokine profile of elderly patients with metabolic syndrome and arterial hypertension. Klinicheskaja gerontologija. – Clinical Gerontology. 2020;26(5-6):5-10. (In Russ.). https://doi.org/10.26347/1607-2499202005-06005-010
16. Edsfeldt A., Grufman H., Asciutto G., Nitulescu M., Persson A. [et al.]. Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis. 2015;241(2):443-449. https://doi.org/10.1016/j.atherosclerosis.2015.05.019
17. Rebrova O. Yu. Statistical analysis of medical data. Application of the STATISTICA application package. Moscow: Media Sfera, 2002. (In Russ.).
18. Drosos G. C., Vedder D., Houben E., Boekel L., Atzeni F. [et al.]. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. 2022;81(6):768-779. https://doi.org/10.1136/annrheumdis-2021-221733
19. England B. R., Thiele G. M., Anderson D. R., Mikuls T. R. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. Review. BMJ. 2018;361:k1036. https://doi.org/10.1136/bmj.k1036
20. Edsfeldt A., Grufman H., Asciutto G., Nitulescu M., Persson A. [et al.]. Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis. 2015;241(2):443-449. https://doi.org/10.1016/j.atherosclerosis.2015.05.019
21. Medina G., Vera-Lastra O., Peralta-Amaro A. L., JiménezArellano M. P., Saavedra M. A. [et al.]. Metabolic syndrome, autoimmunity and rheumatic diseases Review. Pharmacol. Res. 2018;133:277-288. https://doi.org/10.1016/j.phrs.2018.01.009
22. Battineni G., Sagaro G. G., Chintalapudi N., Amenta F., Tomassoni D., Tayebati S. K. Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD). Int. J. Mol. Sci. 2021;22(9):4798. https://doi.org/10.3390/ijms22094798
23. Pirola L., Ferraz J. C. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity Review. World J. Biol. Chem. 2017;8(2):120-128. https://doi.org/10.4331/wjbc.v8.i2.120
24. Baena-Díez J. M., Garcia-Gil M., Comas-Cufí M., Ramos R., Prieto-Alhambra D. [et al.]. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart. 2018;104(2):119-126. https://doi.org/10.1136/heartjnl-2017-311279
25. Haghighatdoost F., Gholami A., Hariri M. Effect of resistant starch type 2 on inflammatory mediators: A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med. 2021;56:102597. https://doi.org/10.1016/j.ctim.2020.102597

Keywords: stable coronary artery disease, type 2 diabetes mellitus, metabolic syndrome, obesity, rheumatoid arthritis, markers of endothelial dysfunction, pro-inflammatory cytokines, antibodies to connective tissue components